Greenline Partners’s iShares Biotechnology ETF IBB Stock Holding History

Greenline Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.1M	Buy	21,569 +4,722	+28%	+$812K	0.42%	58
2026 Q1	$2.84M	Hold	16,847	–	–	0.31%	66
2025 Q4	$2.84M	Hold	16,847	–	–	0.33%	64
2025 Q3	$2.43M	Hold	16,847	–	–	0.3%	67
2025 Q2	$2.13M	Hold	16,847	–	–	0.29%	74
2025 Q1	$2.15M	Hold	16,847	–	–	0.31%	69
2024 Q4	$2.23M	Hold	16,847	–	–	0.31%	67
2024 Q3	$2.45M	Hold	16,847	–	–	0.35%	59
2024 Q2	$2.31M	Hold	16,847	–	–	0.35%	64
2024 Q1	$2.31M	Hold	16,847	–	–	0.37%	59
2023 Q4	$2.29M	Buy	+16,847	New	+$2.06M	0.39%	59

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Greenline Partners's IBB Position: Q2 2026 in Review

Greenline Partners increased its iShares Biotechnology ETF (IBB) stake by 28% in Q2 2026, buying an estimated $812K and bringing the position to 21,569 shares worth $4.1M. The position accounts for 0.42% of the portfolio, ranked #58.

Greenline Partners first reported a position in IBB in Q4 2023 and has held it in 11 quarters since. 955 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Greenline Partners held 21,569 shares of iShares Biotechnology ETF worth $4.1M as of Q2 2026.
Greenline Partners bought 4,722 iShares Biotechnology ETF shares in Q2 2026, an estimated $812K.
iShares Biotechnology ETF made up 0.42% of Greenline Partners's portfolio in Q2 2026, its #58 holding.
Greenline Partners first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 11 quarters since.
955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Greenline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.